India's Strides Arcolab gets FDA nod for two HIV/AIDS new drug applications |
|
|
|
Published
:
Wed, 06 Jun 2007 12:07
|
MUMBAI (Thomson Financial) - India's Strides Arcolab Ltd said it has received tentative approvals from the US Food and Drug Administration for two new drug applications for fixed-dose combination of Lamivudine/Stavudine in HIV/AIDS treatment segment.The company said the approvals are for the combination of Lamivudine/Stavudine 150 mg/40 mg tablets and Lamivudine/Zidovudine 150/300 mg tablets, each co-packaged with Efavirenz 600 mg tablets.The pharma company said both the drugs are under the expedited review provisions of the President's Emergency Plan for Aids Relief (PEPFAR) programme.'We now have approvals for all key front line HIV/AIDS medicines. This, combined with our pipeline of second line drugs, will make us a significant player in the quality, affordable multi-source anti-retroviral (ARV) business segment,' Arun Kumar, vice-chairman and managing director of the company said.rajeshkumar.singh@thomson.comrku/aku/amCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
India's Strides Arcolab buys Diaspa's fermentation facility in Italy 